

Nifty Futures	Level 1	Level 2	Level 3
Resistance	10340	10400	10450
Support	10280	10230	10180

Indices (NSE)	Close	Pts. Chg	% Chg
Nifty	10,348.8	6.5	0.1
Nifty Future (Nov)	10,366.7	8.7	0.1
Nifty Future (Dec)	10,400.6	6.7	0.1
Bank Nifty	25,736.3	-30.4	-0.1
CNX100	10,760.4	5.0	0.0
CNX500	9,207.4	11.7	0.1
CNX Midcap	19,884.2	58.4	0.3

Indices (BSE)	Close	Pts. Chg	% Chg
Sensex	33,588.1	26.5	0.1
BSE-100	10,810.4	9.0	0.1
BSE-200	4,560.3	4.3	0.1
BSE-500	14,572.2	22.1	0.2
Mid Cap	16,836.2	50.8	0.3
Small Cap	17,943.9	90.4	0.5

Sectoral Indices	Close	Pts. Chg	% Chg
BANKEX	29,190.2	0.8	0.0
CAPITAL GOODS	18,415.8	81.9	0.4
REALTY	2,384.1	3.2	0.1
POWER	2,312.5	7.3	0.3
OIL & GAS	16,010.5	57.0	0.4
METAL	14,314.3	-49.5	-0.3
CD	20,823.8	89.7	0.4
AUTO	25,232.9	-57.7	-0.2
TECK	6,123.7	50.9	0.8
IT	10,844.4	139.6	1.3
FMCG	10,313.8	8.6	0.1
HEALTHCARE	13,976.3	31.8	0.2
VIX	13.9	-0.2	-1.2

Exchange	Advance	Decline	Unchg
BSE	1,415	1,284	156
NSE	920	801	72

Volume	Rs (in cr)	% Chg
NSE Cash	29,651.4	-1
BSE Cash	4,422.4	2
NSE F&O	1,134,036.4	71%

Net Inflows/Outflows (Rs in cr)	Buy	Sell	Net
FII	4,395.8	4,322.7	73.2
DII	3,101.4	2,879.2	222.2

Intraday Nifty Outlook

Nifty futures closed 0.08% higher at 10367. Index has formed indecisive candlestick for third consecutive day which shows great indecision amongst market participants. Index is facing resistance around 61.8% retracement of its down move from 10490-10094. Earlier Index has given breakout from the consolidation in which it was moving for past over two months which is a bullish signal for medium term trend. Going ahead index has immediate resistance at 10340, for index to continue its up move it needs to sustain above this level which if it does will open the way for 10400 while support comes at 10280-10230.

Corporate News

Ashok Leyland scripts turnaround in LCV business, to launch 5-6 products

Truck and bus maker Ashok Leyland has turned its LCV (light commercial vehicle) business around, a year after it acquired full control of the joint venture it had with Nissan. The LCV business reported profit before tax (PBT) for the first time during the second quarter of this fiscal and is also generating 8-9 per cent EBITDA margins. "Yes, on a consolidated level we were positive on the PBT side," Gopal Mahadevan, Chief Financial Officer, Ashok Leyland, told BusinessLine. A year ago, Ashok Leyland bought out the shares of all three joint venture companies in LCV from its erstwhile partner Nissan in order to gain full control of the business, which was in its fifth year. Mahadevan attributed the turnaround to rationalising the structure of LCV business and seamless decision making. "We have been running it like a single entity," he added. Dealers have also been happy as uncertainty vanished. They are looking forward to getting more products. Ashok Leyland is preparing to introduce 5-6 new products in the next 12 months in the LCV space both for domestic and international markets. "We will have higher payload vehicles coming and we will also look at left-hand drive markets outside the country," he said. While the company sees opportunities to fill the gaps between Dost and Partner LCVs and in some higher tonnage categories, it will strengthen its presence in the Dost segment, sub-3.5 tonne GVW (gross vehicle weight). (Source - Business Line)

Biocon unveils biosimilar drug for select types of cancer

Biotech major Biocon has launched KRABEVA, a biosimilar product, which can be used to treat certain types of cancer. This biosimilar can be used to treat patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers in India, according to a company statement. The product is being offered to patients at an MRP of ₹ 24,000 for 100 mg /4-ml vials and ₹ 39,990 for 400 mg/16-ml vials. "We believe KRABEVA will be an important addition to oncology portfolio of novel biologics as well as biosimilars, which are making a significant impact in the realm of cancer care in India," said Arun Chandavarkar, CEO and joint MD, Biocon. KRABEVA is a monoclonal anti-body (mAb) developed by Biocon, will help expand access to high quality biosimilar Bevacizumab for cancer patients in India. Bevacizumab is indicated as a first-line treatment of patients with metastatic colorectal cancer (mCRC) and is accepted as a standard treatment option in combination with chemotherapy for patients with non-small-cell lung cancer (NSCLC), metastatic renal cell carcinoma and recurrent ovarian cancer. KRABEVA is being launched post successful completion of phase III clinical trials and approval of company's marketing authorisation application by the Drug Controller General of India. (Source - Business Line)

Bharti family pledges nearly ₹ 7,000 cr to philanthropy

The Bharti family on Thursday said it had decided to pledge 10 per cent of its wealth to philanthropy, including three per cent of their stake in flagship company Bharti Airtel. The commitment would translate to a sum of ₹ 7,000 crore, to be invested in Bharti Foundation, the group's philanthropic arm. With this, the family hopes to significantly step up the scope and reach of Bharti Foundation's activities, and enable it to develop and execute innovative development models to support the underprivileged, including students of its Satya Bharti schools. "Being first-generation entrepreneurs, we feel absolutely privileged that this nation gave us the opportunity to imagine and build world-class businesses. Bharti's DNA has always been about creating a deep positive impact on society through our businesses," Sunil Bharti Mittal, Founder and Chairman, Bharti Enterprises, and Chairman, Bharti Foundation, said. The Founda-



Morning Wealth

Nifty Top 5 Gainers	Close	Pts. Chg	% Chg
INFY	991.3	25.0	2.6
SUNPHARMA	544.8	9.5	1.8
RELIANCE	947.0	16.3	1.7
EICHERMOT	30,620.0	441.8	1.5
TECHM	489.6	7.0	1.5

Nifty Top 5 Losers	Close	Pts. Chg	% Chg
DRREDDY	2,306.3	-54.4	-2.3
ADANI PORTS	407.1	-7.4	-1.8
IBULHSGFIN	1,159.7	-18.9	-1.6
BAJAJ-AUTO	3,264.7	-48.5	-1.5
GAIL	462.9	-6.2	-1.3

Int. Indices	Close	Pts. Chg	% Chg
S&P 500	2,597.1	-2.0	-0.1
DOW	23,526.2	-64.7	-0.3
NASDAQ	6,867.4	4.9	0.1
FTSE	7,417.2	-1.8	0.0
DAX	13,008.6	-6.5	0.0
CAC	5,379.5	26.8	0.5
NIKKEI	22,446.1	-77.0	-0.3
Hangseng	29,748.6	40.7	0.1
Straits Times	3,433.1	9.9	0.3

ADR	Close	Pts. Chg	% Chg
HDFC Bank	97.9	1.2	1.3
ICICI Bank	9.8	0.0	0.2
Infosys	15.2	0.1	0.5
TATA Motors	32.9	0.2	0.5
Wipro	5.3	-0.1	-1.1

Currencies	Close	Pts. Chg	% Chg
Dollar Index	93.1	-0.1	-0.1
USD/INR	64.6	-0.3	-0.5
EURO/INR	76.5	0.2	0.2
USD/YEN	111.3	0.1	0.1

Commodities	Close	Pts. Chg	% Chg
Gold (spot) Rs	29,439	-91	-0.3
Silver (spot) Rs	39,392	-177	-0.45
Crude (Brent) \$	63.4	-0.12	-0.19
Crude Oil (WTI) \$	58.4	0.46	0.79

Economy

President signs Ordinance to amend Bankruptcy Code

The government has put in place the legal provisions to disallow wilful defaulters and unscrupulous entities from bidding for stressed assets with President Ram Nath Kovind on Thursday approving an Ordinance to amend the Insolvency and Bankruptcy Code. The Union Cabinet had on Wednesday approved the promulgation of the Ordinance. A Bill to replace the Ordinance is expected to be tabled in Parliament in the Winter Session. It amends Sections 2, 5, 25, 30, 35 and 240 of the Code, and inserts new Sections 29A and 235A in the Code. "The amendments aim to keep out such persons who have wilfully defaulted, are associated with non-performing assets, or are habitually non-compliant and, therefore, are likely to be a risk to successful resolution of insolvency of a company," said an official release. It also places restrictions for such persons to participate in the resolution or liquidation process. Accordingly, companies, promoters and associate companies undergoing insolvency resolution or liquidation under the Code would not be eligible to bid for the stressed assets. The Ordinance provides such checks by specifying that the Committee of Creditors (CoC) ensure the viability and feasibility of the resolution plan before approving it. (Source: Business line)

International News

Chinese Rout Abates as Stocks in Asia Trade Mixed: Markets Wrap

Asian stocks traded mixed as Japanese equities declined after a holiday, while a sudden sell-off that sent Chinese equities plunging on Thursday fizzled. The dollar was modestly firmer and the euro maintained gains as the economy picked up momentum. With U.S. markets closed and most American investors out for the Thanksgiving holiday, traders in Tokyo are back at their desks facing losses -- the yen has strengthened since Japanese shares last traded. Both the Topix index and the Nikkei 225 Stock Average declined. The Hang Seng Index advanced with Chinese stocks traded in Hong Kong climbing. The severity of Thursday's slump in Chinese stocks caught some traders off-guard and left some questioning why authorities decided not to step in this time as they have often done in the past. Global stocks are heading into the final weeks of 2017 at record highs as investors place their faith in economic growth and an earnings' expansion. Thursday's selloff in Chinese shares, which triggered a 1 percent slump in Hong Kong's Hang Seng Index, was a reminder to international investors that turbulence in mainland Chinese markets can spread. (Source: Bloomberg)

Major Bulk Deal (NSE)

Scrip Name	Qty	Type	Client Name	Trade Price
No Major Bulk deals				

Major Bulk Deal (BSE)

Scrip Name	Qty	Type	Client Name	Trade Price
AIAENG	600,000	SELL	JWALAMUKHI INVESTMENT HOLDINGS	1,446
SYNGENE	1,950,000	SELL	STEADVIEW CAPITAL MAURITIUS LIMITED	516.92



EVENTS CALENDAR

Monday	Tuesday	Wednesday	Thursday	Friday
20-Nov-2017 Results— Economic Indicators— US—	21-Nov-2017 Results – Dixon, Economic Indicators – US—	22-Nov-2017 Results - Economic Indicators— US– Jobless Claims	23-Nov-2017 Results — Economic Indicators— US—	24-Nov-2017 Results— Economic Indicators— US—
27-Nov-2017 Results— Apollo Hospi- tal, Economic Indicators— US—	28-Nov-2017 Results – Dixon, Economic Indicators – US—	29-Nov-2017 Results - Economic Indicators— US—	30-Nov-2017 Results — Economic Indicators— GDP Growth Rate US– Jobless Claims	01-Dec-2017 Results— Economic Indicators— US—
4-Dec-2017 Results— Economic Indicators— US—	5-Dec-2017 Results – Economic Indicators – US—	6-Dec-2017 Results - Economic Indicators— US—	7-Dec-2017 Results — Economic Indicators— US– Jobless Claims	8-Dec-2017 Results— Economic Indicators— US—

Green: Corporate Event, Red: Economic Events, Dark Blue: US Events/ UK Events

(Source: Bloomberg and BSE)

**Disclaimer Appendix****Analyst (s) holding in the Stock : Nil****Analyst (s) Certification:**

We analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer (s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation (s) or view (s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the BP Equities Pvt. Ltd. (Institutional Equities).

General Disclaimer

This report has been prepared by the research department of BP EQUITIES Pvt. Ltd, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.

BP EQUITIES Pvt. Ltd have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice.

Recipients of this material should rely on their own investigations and take their own professional advice. BP EQUITIES Pvt. Ltd or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. BP EQUITIES Pvt. Ltd. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

BP EQUITIES Pvt. Ltd and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to BP EQUITIES Pvt. Ltd or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Corporate Office:

4th floor,
Rustom Bldg,
29, Veer Nariman Road, Fort,
Mumbai-400001
Phone- +91 22 6159 6464
Fax-+91 22 6159 6160
Website- www.bpwealth.com

Registered Office:

24/26, 1st Floor, Cama Building,
Dalal street, Fort,
Mumbai-400001
BP Wealth Management Pvt. Ltd.
CIN No: U67190MH2005PTC154591
BP Equities Pvt. Ltd.
CIN No: U67120MH1997PTC107392